Renata Medical raises $25M Series D for pediatric heart devices
What's the deal? Renata Medical, a Newport Beach, California medical technology company focused on children with congenital heart disease, has closed a $25 million Series D round. Healthcare investment firm ARCHIMEDDealroom has a profile for this one. Try Dealroom → led the round, with existing investors participating.
What's the endgame? The company builds cardiovascular devices designed specifically for children. Its lead product, the Minima Stent System, is the first balloon-expandable growth stent made for neonates, infants, and young children with pulmonary artery stenosis or coarctation of the aorta.
Where the money goes: Renata will fund expanded US commercialization of Minima, entry into international markets, its pipeline of pediatric-specific technology, and further clinical evidence generation.
Why now? Minima received FDA premarket approval in August 2024 and launched commercially that year. In August 2025, the Centers for Medicare & Medicaid Services granted the device a New Technology Add-on Payment designation, giving hospitals extra reimbursement support.
"Adoption of the Minima Stent System has exceeded our expectations since commercial launch in 2024," said Dustin Armer, co-founder and chief executive officer of Renata Medical.
Investor view: ARCHIMED, which manages €9 billion across its funds, sees a clear unmet need. "Children born with congenital heart defects have too often been treated with devices built for adults and many face repeat procedures simply because their implants cannot grow with them," said André-Michel Ballester, managing partner at ARCHIMED and former chief executive officer of LivaNovaDealroom has a profile for this one. Try Dealroom →.
The signal: At $25 million, the round sits mid-pack for its category, but the CMS reimbursement designation and FDA approval mark a shift toward devices purpose-built for pediatric patients rather than adapted adult hardware.
Read more: PR Newswire
Image credit: Renata Medical
